SYDNEY –
A last-minute decision by retail conglomerate Wesfarmers to halt a proposed capital rescue for its largest Priceline franchisee, Infinity Pharmacy Group, has pushed the operator into external administration and left more than A$400 million of creditor exposure unresolved.
The failure of the recapitalisation, finalised in December 2025, led to receivers being appointed and dozens of Infinity-operated Priceline stores placed under external management. The move severs a prospective equity lifeline and shifts immediate responsibility for stabilising the network to insolvency administrators and secured lenders.
Why this matters for the sector
The collapse of Infinity – a major franchisee within the Priceline retail banner – tightens the link between wholesale distribution, franchise governance and balance-sheet risk within Australia’s pharmacy sector. Wesfarmers completed its acquisition of Priceline’s operator, Australian Pharmaceutical Industries (API), in 2022, integrating API into its health division as a strategic retail and distribution asset. The acquisition was cleared by competition authorities at that time, leaving Wesfarmers with contractual and commercial ties across the Priceline franchise network. That clearance, alongside the sector’s long‑standing community pharmacy rules, framed expectations that the group would underpin supply relationships between the wholesaler and independent franchisees. The National Health Act and associated pharmacy location and ownership rules sit in the background of these arrangements, shaping how community pharmacies operate, consolidate and compete.
Key facts and timeline
- Receivership and administration actions began in mid-December 2025; receivers were appointed on December 17, 2025, after a proposed recapitalisation was abandoned.
- A first creditors’ meeting was convened on December 31, 2025, setting out the framework for investigations, committee formation and potential deeds of company arrangement.
- Aggregate creditor exposure associated with Infinity exceeds A$400 million, spanning secured lenders, trade creditors, landlords and tax authorities.
- API (Priceline’s franchisor/wholesaler) is reported to be owed roughly A$110 million by Infinity, while major banks – Westpac, NAB and Commonwealth Bank – are collectively reported to be owed about A$145 million.
- Insolvency advisers KPMG were appointed as receivers and are working with Teneo, which is acting as voluntary administrators for parts of the business.
Receivership, store operations and creditor exposure
Administrators and receivers have continued to operate a substantial portion of Infinity’s store network while pursuing creditor processes, a standard approach designed to preserve value and maintain continuity of patient access to medicines. Reports indicate more than 50 stores were placed under receivership in December 2025; administrators are operating stores with staff retained and stock on shelves while creditors’ meetings proceed and short‑term funding lines are maintained. The insolvency process has crystallised sizeable secured lender claims and trade creditor balances, exposing the scale of leverage that financed Infinity’s expansion and the degree to which working-capital risk had migrated from the franchisee’s balance sheet to suppliers.
Operational and commercial attribution
Internal communications from Wesfarmers’ health division characterise Infinity’s collapse as the result of an aggressive acquisition strategy funded by high-cost debt that outpaced the business’s ability to meet supplier and lender obligations. The company has emphasised its role as a supplier and franchisor rather than an equity underwriter of franchisee risk, and signalled that the decision to step back from a capital injection followed extended engagement, due diligence and consideration of its obligations to other franchisees and shareholders.
“This expansion came at the expense of Infinity meeting its financial obligations, including not paying us and various other creditors, to supply products.”
Wesfarmers Health chief customer officer Richard Pearson
The attribution sets up a potential line of inquiry for creditors and regulators: whether franchise agreements, reporting covenants and risk‑sharing mechanisms were sufficient to flag emerging stress before debts to wholesalers and banks accumulated at this scale.
Buy-side interest and sale process
Insolvency advisers have been reported to be preparing a sale process for the store network. Early interest has been flagged from rival pharmacy groups and other industry participants; advisers are understood to be assessing options for selling individual stores, bundles of locations or larger portfolios within the wider Infinity network. Any transaction will need to navigate community pharmacy ownership and location restrictions, as well as the requirement that pharmacies remain registered and able to dispense Pharmaceutical Benefits Scheme (PBS) medicines under Commonwealth rules. For administrators, the task is to balance secured creditors’ recovery, franchise continuity, regulatory compliance and the practical need to keep front‑line pharmacy services operating.
Sector implications and governance considerations
The episode highlights several established structural considerations in the Australian pharmacy market: the interdependence of wholesale supply and franchisor-franchisee cashflows; constraints placed by community pharmacy ownership and location rules; and the exposure of networks when growth is funded by short-term, high-interest debt. It also underscores the degree to which large corporate parents and wholesalers are now central to the resilience of franchised community pharmacies, even when they are not direct owners.
The insolvency process will test contractual protections between API (as franchisor and wholesale supplier), franchisees and secured lenders, and may prompt renewed scrutiny of franchise governance, credit terms, disclosure standards and sector concentration. Policy makers and regulators are likely to watch closely for any impact on regional or lower‑income communities’ access to pharmacy services, and for precedents that the eventual restructuring may set for future distressed franchisees.
A confirmed next procedural step
KPMG, as receiver, and Teneo, as voluntary administrator, are conducting an active sale and restructuring process for Infinity’s stores as the formal creditor and receivership procedures progress. Outcomes from the next round of creditors’ meetings and any announced sale processes will determine whether Infinity’s footprint is preserved largely intact under new ownership or broken up, and will offer an early indication of how risk will be shared between wholesalers, banks and franchisees in the sector’s next phase.
